{"id":"https://openalex.org/W4391708005","doi":"https://doi.org/10.1212/wnl.0000000000208058","title":"Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis","display_name":"Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis","publication_year":2024,"publication_date":"2024-02-09","ids":{"openalex":"https://openalex.org/W4391708005","doi":"https://doi.org/10.1212/wnl.0000000000208058","pmid":"https://pubmed.ncbi.nlm.nih.gov/38335474","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11067693"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000208058","doi":"https://doi.org/10.1212/wnl.0000000000208058","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000208058","pdf_url":"https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000208058","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000208058","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065754098","display_name":"Douglas Lorne Arnold","orcid":"https://orcid.org/0000-0003-4266-0106","observed_orcids":["https://orcid.org/0000-0003-4266-0106","https://orcid.org/0000-0002-0805-7672"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":true,"raw_author_name":"Douglas L. Arnold","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023035078","display_name":"Colm Elliott","orcid":"https://orcid.org/0000-0002-3004-523X","observed_orcids":["https://orcid.org/0000-0002-3004-523X"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":false,"raw_author_name":"Colm Elliott","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":"https://orcid.org/0000-0002-3004-523X","affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102747029","display_name":"Emily C. Martin","orcid":"https://orcid.org/0000-0002-2011-3905","observed_orcids":["https://orcid.org/0000-0002-2011-3905"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":false,"raw_author_name":"Emily C. Martin","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037407336","display_name":"Yann Hyvert","orcid":"https://orcid.org/0009-0006-4700-0296","observed_orcids":["https://orcid.org/0009-0006-4700-0296"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":false,"raw_author_name":"Yann Hyvert","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050196672","display_name":"Davorka Tomic","orcid":"https://orcid.org/0000-0002-1484-1850","observed_orcids":["https://orcid.org/0000-0002-1484-1850"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":false,"raw_author_name":"Davorka Tomic","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031171090","display_name":"Xavier Montalb\u00e1n","orcid":"https://orcid.org/0000-0002-0098-9918","observed_orcids":["https://orcid.org/0000-0002-0098-9918"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4210133916","display_name":"NeuroRx Research (Canada)","ror":"https://ror.org/02r8axs93","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210133916"]},{"id":"https://openalex.org/I4396570551","display_name":"Centre d'Esclerosi M\u00faltiple de Catalunya","ror":"https://ror.org/01kzbqm05","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4396570551"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA","DE","ES","US"],"is_corresponding":false,"raw_author_name":"Xavier Montalban","raw_affiliation_strings":["From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","EMD Serono (E.C.M.), Billerica, MA","From the Montreal Neurological Institute (D.L.A.), McGill University","NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","The Healthcare Business of Merck KGaA (Y.H.)"],"raw_orcid":"https://orcid.org/0000-0002-0098-9918","affiliations":[{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada; EMD Serono (E.C.M.), Billerica, MA; The Healthcare Business of Merck KGaA (Y.H.); Ares Trading SA (D.T.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany; and Centre d'Esclerosi M\u00faltiple de Catalunya (Cemcat) (X.M.), Hospital Universitario Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"]},{"raw_affiliation_string":"EMD Serono (E.C.M.), Billerica, MA","institution_ids":["https://openalex.org/I4210111614"]},{"raw_affiliation_string":"From the Montreal Neurological Institute (D.L.A.), McGill University","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"NeuroRx Research (D.L.A., C.E.), Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I4210133916"]},{"raw_affiliation_string":"The Healthcare Business of Merck KGaA (Y.H.)","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5065754098"],"corresponding_institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4210111614","https://openalex.org/I4210133916","https://openalex.org/I4396570551","https://openalex.org/I4405266695","https://openalex.org/I5023651"],"apc_list":null,"apc_paid":null,"fwci":7.7669,"has_fulltext":true,"cited_by_count":32,"citation_normalized_percentile":{"value":0.98316936,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":99},"biblio":{"volume":"102","issue":"5","first_page":"e208058","last_page":"e208058"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/evobrutinib","display_name":"evobrutinib","score":1.0},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.996999979019165},{"id":"https://openalex.org/keywords/chronic-active-lesions","display_name":"chronic active lesions","score":0.984000027179718},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.8899999856948853},{"id":"https://openalex.org/keywords/lesion-volume","display_name":"lesion volume","score":0.6990000009536743},{"id":"https://openalex.org/keywords/dose-dependent-effects","display_name":"dose-dependent effects","score":0.6370000243186951},{"id":"https://openalex.org/keywords/demyelination","display_name":"demyelination","score":0.8059999942779541},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.625},{"id":"https://openalex.org/keywords/dimethyl-fumarate","display_name":"dimethyl fumarate","score":0.7829999923706055}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.8374642729759216},{"id":"https://openalex.org/C2781156865","wikidata":"https://www.wikidata.org/wiki/Q827023","display_name":"Lesion","level":2,"score":0.6935387849807739},{"id":"https://openalex.org/C2779830541","wikidata":"https://www.wikidata.org/wiki/Q1622829","display_name":"Microglia","level":3,"score":0.5720288157463074},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5472168922424316},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.5103501677513123},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.5049198269844055},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.32845205068588257},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27856165170669556},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.17028149962425232},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16484257578849792},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.06732591986656189}],"mesh":[{"descriptor_ui":"D000069462","descriptor_name":"Dimethyl Fumarate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1212/wnl.0000000000208058","doi":"https://doi.org/10.1212/wnl.0000000000208058","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000208058","pdf_url":"https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000208058","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11067693","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11067693","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11067693/pdf/WNL-2023-002096.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Text"},{"id":"pmid:38335474","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38335474","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1212/wnl.0000000000208058","doi":"https://doi.org/10.1212/wnl.0000000000208058","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000208058","pdf_url":"https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000208058","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308604","display_name":"Biogen","ror":"https://ror.org/02jqkb192"},{"id":"https://openalex.org/F4320308970","display_name":"Teva Pharmaceutical Industries","ror":"https://ror.org/01wfv3m53"},{"id":"https://openalex.org/F4320309052","display_name":"Alexion Pharmaceuticals","ror":"https://ror.org/031ywxc85"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309432","display_name":"F. Hoffmann-La Roche","ror":"https://ror.org/00by1q217"},{"id":"https://openalex.org/F4320311647","display_name":"Merck KGaA","ror":"https://ror.org/04b2dty93"},{"id":"https://openalex.org/F4320330529","display_name":"MedDay Pharmaceuticals","ror":"https://ror.org/01taed346"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332200","display_name":"EMD Serono","ror":"https://ror.org/027zrs220"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4391708005.pdf","grobid_xml":"https://content.openalex.org/works/W4391708005.grobid-xml"},"referenced_works_count":36,"referenced_works":["https://openalex.org/W1763205699","https://openalex.org/W1828576284","https://openalex.org/W2056047022","https://openalex.org/W2146358032","https://openalex.org/W2342700917","https://openalex.org/W2514919331","https://openalex.org/W2542350582","https://openalex.org/W2562977489","https://openalex.org/W2565433170","https://openalex.org/W2603095844","https://openalex.org/W2620266814","https://openalex.org/W2884726359","https://openalex.org/W2896014118","https://openalex.org/W2905522261","https://openalex.org/W2935804657","https://openalex.org/W2944582362","https://openalex.org/W2966475886","https://openalex.org/W2967069002","https://openalex.org/W2970233240","https://openalex.org/W3033968144","https://openalex.org/W3047313223","https://openalex.org/W3080676737","https://openalex.org/W3105122247","https://openalex.org/W3124374877","https://openalex.org/W3155793436","https://openalex.org/W3179712487","https://openalex.org/W3194931521","https://openalex.org/W4210366840","https://openalex.org/W4211048507","https://openalex.org/W4220747781","https://openalex.org/W4253381763","https://openalex.org/W4280531603","https://openalex.org/W4285744151","https://openalex.org/W4296489093","https://openalex.org/W4306765088","https://openalex.org/W4367304943"],"related_works":["https://openalex.org/W4389366647","https://openalex.org/W4362472973","https://openalex.org/W4389464500","https://openalex.org/W4392376725","https://openalex.org/W2966319593","https://openalex.org/W4367304943","https://openalex.org/W3205572691","https://openalex.org/W4389366547","https://openalex.org/W2944582362","https://openalex.org/W4367304111"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Chronic":[3],"active":[4],"lesions":[5,12,216],"(CALs)":[6],"are":[7],"demyelinated":[8],"multiple":[9],"sclerosis":[10],"(MS)":[11],"with":[13,200,204,218,264,269],"ongoing":[14],"microglia/macrophage":[15],"activity,":[16],"resulting":[17],"in":[18,59,67,123,194,198,267],"irreversible":[19],"neuronal":[20],"damage":[21],"and":[22,80,125,133,182,221],"axonal":[23],"loss.":[24,223],"Evobrutinib":[25,190],"is":[26,210],"a":[27,60,195,201],"highly":[28],"selective,":[29],"covalent,":[30],"CNS-penetrant,":[31],"Bruton":[32],"tyrosine":[33],"kinase":[34],"inhibitor.":[35],"This":[36,209,246],"post":[37],"hoc":[38],"analysis":[39],"evaluated":[40],"the":[41,83,87,117,255],"effect":[42,113],"of":[43,54,86,121,131,257],"evobrutinib":[44,132,170,205,213,253],"on":[45,107,233,260],"slowly":[46],"expanding":[47],"lesion":[48,102],"(SEL)":[49],"volume,":[50],"an":[51],"MRI":[52,79,261],"marker":[53],"CALs,":[55],"assessed":[56,81,259],"baseline-week":[57],"48":[58],"phase":[61],"2,":[62],"double-blind,":[63],"randomized":[64],"trial":[65],"(NCT02975349)":[66],"relapsing":[68],"MS":[69],"(RMS).":[70],"METHODS:":[71],")":[72],"over":[73],"time.":[74],"SELs":[75,258],"were":[76,140],"identified":[77],"by":[78,82,99],"Jacobian":[84],"determinant":[85],"nonlinear":[88],"deformation":[89],"from":[90],"baseline":[91,100,176,263],"to":[92,231],"week":[93,108,265],"48.":[94],"SEL":[95,164,192],"volume":[96,103,165,193,256],"analysis,":[97],"stratified":[98,118,126],"T2":[101],"tertiles,":[104],"was":[105,114,166],"based":[106],"48/end-of-treatment":[109],"status":[110],"(completers/non-completers).":[111],"Treatment":[112],"analyzed":[115],"using":[116],"Hodges-Lehmann":[119],"estimate":[120],"shift":[122],"distribution":[124],"Wilcoxon":[127],"rank-sum":[128],"test.":[129],"Comparisons":[130],"DMF":[134],"vs":[135,154,172],"placebo/evobrutinib":[136],"25":[137,158],"mg":[138,152,159,207],"QD":[139],"made.":[141],"Subgroup":[142],"analyses":[143],"used":[144],"pooled":[145],"treatment":[146],"groups":[147],"(evobrutinib":[148],"high":[149,171],"dose":[150,156,174],"[75":[151],"QD/BID]":[153],"low":[155,173],"[placebo/evobrutinib":[157],"QD]).":[160],"RESULTS:":[161],"=":[162],"0.011).":[163],"significantly":[167],"reduced":[168,191],"for":[169],"within":[175],"Expanded":[177],"Disability":[178],"Status":[179],"Scale":[180],"\u22653.5":[181],"longer":[183],"disease":[184],"duration":[185],"(\u22658.5":[186],"years)":[187],"subgroups.":[188],"DISCUSSION:":[189],"dose-dependent":[196],"manner":[197],"RMS,":[199],"significant":[202],"reduction":[203],"75":[206],"BID.":[208],"evident":[211],"that":[212,252],"affects":[214],"brain":[215],"associated":[217],"chronic":[219],"inflammation":[220],"tissue":[222],"TRIAL":[224],"REGISTRATION":[225],"INFORMATION:":[226],"ClinicalTrials.gov":[227,232],"number:":[228],"NCT02975349.":[229],"Submitted":[230],"November":[234],"29,":[235],"2016.":[236],"First":[237],"patient":[238],"enrolled:":[239],"March":[240],"7,":[241],"2017.":[242],"CLASSIFICATION":[243],"OF":[244],"EVIDENCE:":[245],"study":[247],"provides":[248],"Class":[249],"II":[250],"evidence":[251],"reduces":[254],"comparing":[262],"48,":[266],"patients":[268],"RMS.":[270]},"counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":7}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2024-02-10T00:00:00"}